Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCRL | Q16602 | 19/20 | 0.50 |
| ▸ | RAMP1 | O60894 | 11/20 | 0.49 |
| ▸ | CALCA | P06881 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31126001 | 1.00 | CALCRL (0.50) | CALCRLRAMP1CALCA | |
| SCHEMBL29550041 | 1.00 | CALCRL (0.50) | CALCRLRAMP1CALCA | |
| SCHEMBL976476 | 0.85 | CALCRL (0.50) | CALCRLRAMP1CALCA | |
| SCHEMBL838209 | 0.85 | CALCRL (0.50) | CALCRLRAMP1 | |
| SCHEMBL22110811 | 0.85 | CALCRL (0.51) | CALCRLRAMP1 | |
| SCHEMBL31039442 | 0.85 | CALCRL (0.50) | CALCRLRAMP1 | |
| SCHEMBL978566 | 0.85 | CALCRL (0.50) | CALCRLRAMP1 | |
| SCHEMBL977185 | 0.85 | CALCRL (0.50) | CALCRLRAMP1 | |
| SCHEMBL2263515 | 0.85 | CALCA (0.50) | CALCRLRAMP1CALCA | |
| SCHEMBL976576 | 0.85 | CALCA (0.50) | CALCRLRAMP1CALCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4653049-A2 | CGRP ANTAGONIST COMPOUNDS | Nxera Pharma UK Limited (GB) | 2025-11-26 | — | — | EP | disclosed |
| EP-3983416-B1 | CGRP ANTAGONIST COMPOUNDS | NXERA PHARMA UK LTD (GB) | 2025-09-03 | — | — | EP | disclosed |
| EP-3983417-B1 | CGRP ANTAGONIST COMPOUNDS | NXERA PHARMA UK LTD (GB) | 2025-09-03 | — | — | EP | disclosed |
| US-12344621-B2 | CGRP antagonist compounds | NXERA PHARMA UK LIMITED (GB) | 2025-07-01 | — | — | US | disclosed |
| US-20250136616-A1 | CGRP ANTAGONIST COMPOUNDS | HEPTARES THERAPEUTICS LIMITED (GB) | 2025-05-01 | — | — | US | disclosed |
| US-12227521-B2 | CGRP antagonist compounds | NXERA PHARMA UK LIMITED (GB) | 2025-02-18 | — | — | US | disclosed |
| US-20220306651-A1 | CGRP ANTAGONIST COMPOUNDS | NXERA PHARMA UK LIMITED (GB) | 2022-09-29 | — | — | US | disclosed |
| US-20220251110-A1 | CGRP ANTAGONIST COMPOUNDS | NXERA PHARMA UK LIMITED (GB) | 2022-08-11 | — | — | US | disclosed |
| EP-3983417-A1 | CGRP ANTAGONIST COMPOUNDS | Heptares Therapeutics Limited (GB) | 2022-04-20 | — | — | EP | disclosed |
| EP-3983416-A1 | CGRP ANTAGONIST COMPOUNDS | Heptares Therapeutics Limited (GB) | 2022-04-20 | — | — | EP | disclosed |
| US-8765759-B2 | Monocyclic CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2014-07-01 | — | — | US | disclosed |
| EP-2271346-B1 | MONOCYCLIC CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2014-01-01 | — | — | EP | disclosed |
| US-20120121508-A1 | RADIOLABELED CGRP ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120121508-A1 | RADIOLABELED CGRP ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120121508-A1 | RADIOLABELED CGRP ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2012-05-17 | — | — | US | disclosed |
| WO-2011014383-A1 | RADIOLABELED CGRP ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2011-02-03 | — | — | WO | disclosed |
| US-20110021516-A1 | MONOCYCLIC CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP (US) | 2011-01-27 | — | — | US | disclosed |
| US-20110021516-A1 | MONOCYCLIC CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP (US) | 2011-01-27 | — | — | US | disclosed |
| US-20110021516-A1 | MONOCYCLIC CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP (US) | 2011-01-27 | — | — | US | disclosed |
| WO-2009120652-A2 | MONOCYCLIC CGRP RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2009-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220251110-A1 | CGRP ANTAGONIST COMPOUNDS | CALCRL, CALCR, OPRL1 | CALCRL 1/4885RAMP1 49/4885CALCA 4/4885 |
| US-20110021516-A1 | MONOCYCLIC CGRP RECEPTOR ANTAGONISTS | CCKAR, CALCRL, CCKBR | CALCRL 2/4885RAMP1 169/4885CALCA 14/4885 |
| US-20250136616-A1 | CGRP ANTAGONIST COMPOUNDS | CALCRL, CALCR, OPRL1 | CALCRL 1/4885RAMP1 49/4885CALCA 4/4885 |
| US-20220306651-A1 | CGRP ANTAGONIST COMPOUNDS | CALCRL, CALCR, CALCA | CALCRL 1/4885RAMP1 67/4885CALCA 3/4885 |
| US-20120121508-A1 | RADIOLABELED CGRP ANTAGONISTS | CALCRL, CALCR, GRPR | CALCRL 1/4885RAMP1 54/4885CALCA 12/4885 |
| US-12227521-B2 | CGRP antagonist compounds | CALCRL, CALCR, OPRL1 | CALCRL 1/4885RAMP1 49/4885CALCA 4/4885 |
| US-12344621-B2 | CGRP antagonist compounds | CALCRL, CALCR, CALCA | CALCRL 1/4885RAMP1 63/4885CALCA 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.